JP2015508774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508774A5 JP2015508774A5 JP2014557754A JP2014557754A JP2015508774A5 JP 2015508774 A5 JP2015508774 A5 JP 2015508774A5 JP 2014557754 A JP2014557754 A JP 2014557754A JP 2014557754 A JP2014557754 A JP 2014557754A JP 2015508774 A5 JP2015508774 A5 JP 2015508774A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aqueous
- composition according
- treatment
- antibody pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261599827P | 2012-02-16 | 2012-02-16 | |
| US61/599,827 | 2012-02-16 | ||
| PCT/US2013/026034 WO2013123114A2 (en) | 2012-02-16 | 2013-02-14 | Antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097486A Division JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508774A JP2015508774A (ja) | 2015-03-23 |
| JP2015508774A5 true JP2015508774A5 (https=) | 2016-03-24 |
| JP6345123B2 JP6345123B2 (ja) | 2018-06-20 |
Family
ID=47997774
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557754A Expired - Fee Related JP6345123B2 (ja) | 2012-02-16 | 2013-02-14 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
| JP2018097486A Active JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097486A Active JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10160808B2 (https=) |
| EP (1) | EP2814468B1 (https=) |
| JP (2) | JP6345123B2 (https=) |
| CN (1) | CN104271122A (https=) |
| AU (2) | AU2013221635B2 (https=) |
| CA (1) | CA2864539C (https=) |
| ES (1) | ES2732243T3 (https=) |
| IL (1) | IL233976B (https=) |
| MX (1) | MX370199B (https=) |
| NZ (1) | NZ629204A (https=) |
| WO (1) | WO2013123114A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1181054A1 (en) | 1999-06-01 | 2002-02-27 | Biogen, Inc. | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| DE60236735D1 (de) | 2001-04-13 | 2010-07-29 | Biogen Idec Inc | Antikörper gegen vla-1 |
| SMT201800552T1 (it) | 2010-01-06 | 2018-11-09 | Dyax Corp | Proteine che legano la callicreina plasmatica |
| KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| JP6345123B2 (ja) * | 2012-02-16 | 2018-06-20 | サンタラス， インコーポレイテッド | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| AU2014240045A1 (en) | 2013-03-15 | 2015-09-10 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| JP2017514458A (ja) | 2014-03-12 | 2017-06-08 | プロセナ バイオサイエンシーズ リミテッド | Ｌｇ４−５に対して特異的な抗−ラミニン４抗体 |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| BR112017006533A2 (pt) * | 2014-09-29 | 2017-12-19 | Cook General Biotechnology Llc | usos de trealose em suspensões celulares |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| US20160367180A1 (en) * | 2015-06-17 | 2016-12-22 | Obsevera, Inc. | Apparatus and method of conducting medical evaluation of add/adhd |
| EP3350226A2 (en) * | 2015-09-16 | 2018-07-25 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP3387018A1 (en) * | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CA3017743A1 (en) * | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| MA45381A (fr) * | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
| EP3479819B1 (en) * | 2016-06-30 | 2024-01-24 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
| MA49645A (fr) | 2017-07-20 | 2021-03-31 | Univ Virginia Patent Foundation | Procédés de traitement ou de prévention d'un trouble neurologique du système immunitaire |
| US20210100837A1 (en) * | 2017-12-14 | 2021-04-08 | The University Of Chicago | Treatment of fibrosis with genetically-engineered macrophages |
| CN111787948A (zh) * | 2018-02-09 | 2020-10-16 | 健玛保 | 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途 |
| MA54752A (fr) | 2019-01-14 | 2021-11-24 | Univ Virginia Patent Foundation | Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux |
| BR112021021099A2 (pt) * | 2019-04-23 | 2021-12-14 | Sanofi Sa | Formulações de anticorpos estáveis, de baixa viscosidade, e usos das mesmas |
| JP7656587B2 (ja) * | 2019-08-15 | 2025-04-03 | ジェンマブ エー／エス | Ｃｄ３およびｃｄ２０に対する二重特異性抗体を含む薬学的組成物、ならびにそれらの使用 |
| EP4090427A1 (en) | 2020-01-13 | 2022-11-23 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| MX2022013797A (es) | 2020-05-08 | 2022-11-30 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
| KR20230066040A (ko) | 2020-09-10 | 2023-05-12 | 젠맵 에이/에스 | 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 |
| CA3189883A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| CN116782933A (zh) | 2020-09-10 | 2023-09-19 | 健玛保 | 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| CA3190376A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| JP2024518536A (ja) * | 2021-05-12 | 2024-05-01 | アナプティスバイオ インコーポレイティッド | 抗体組成物 |
| WO2026062206A2 (en) | 2024-09-20 | 2026-03-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | A method of differentiating human embryonic stem cells into beta cells via camp signalling pathway promotion |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5391481A (en) | 1990-08-31 | 1995-02-21 | The Trustees Of Columbia University | Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DK0626861T4 (da) | 1992-01-13 | 2004-08-16 | Biogen Inc | Behandling af astma. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen, Inc. | Rekombinante anti-vla4 antikörpermoleküle |
| ATE161730T1 (de) | 1993-02-09 | 1998-01-15 | Biogen Inc | Antikörper zur behandlung von insulinabhängigen diabetes |
| US6111598A (en) | 1993-11-12 | 2000-08-29 | Peveo, Inc. | System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| HU220799B1 (hu) | 1994-01-25 | 2002-05-28 | Elan Pharmaceuticals, Inc. | Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| WO1995028961A1 (en) | 1994-04-26 | 1995-11-02 | Kanebo, Ltd. | Remedy for rheumatoid arthritis |
| JPH08131185A (ja) | 1994-11-14 | 1996-05-28 | Sumitomo Electric Ind Ltd | マウスｖｌａ−１分子に対するモノクローナル抗体 |
| JPH08160972A (ja) | 1994-12-01 | 1996-06-21 | Sega Enterp Ltd | エフェクト制御方法、制御装置およびこれを利用したカラオケ装置 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9516399D0 (en) | 1995-08-10 | 1995-10-11 | Camelot Superabsorbents Ltd | Process for the production of water-absorbing compositions |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| KR100308764B1 (ko) | 1995-08-29 | 2001-12-17 | 마나배게이사꾸 | 키메라동물및그의제작법 |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| GB9519667D0 (en) | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US6127524A (en) | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| CA2635352C (en) * | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| HUP0202048A3 (en) | 1998-05-22 | 2006-11-28 | Boys Town Nat Res Hospital Oma | Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| CA2340333A1 (en) | 1998-10-06 | 2000-04-13 | Biogen, Inc. | Crystals of the alpha 1 beta 1 integrin i-domain and their use |
| PT1173201E (pt) | 1999-04-22 | 2005-08-31 | Biogen Idec Inc | Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina |
| EP1181054A1 (en) | 1999-06-01 | 2002-02-27 | Biogen, Inc. | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| EP1408839A1 (de) | 1999-06-17 | 2004-04-21 | Kai Dr. Desinger | Chirurgische sonde zur minimal invasiven gewebeentnahme |
| WO2001073444A2 (en) | 2000-03-28 | 2001-10-04 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| DE10028402A1 (de) | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| US7153944B2 (en) | 2000-07-31 | 2006-12-26 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
| DE60236735D1 (de) | 2001-04-13 | 2010-07-29 | Biogen Idec Inc | Antikörper gegen vla-1 |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| WO2003068262A1 (en) | 2002-02-14 | 2003-08-21 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
| JP5138867B2 (ja) | 2002-08-01 | 2013-02-06 | イミューノメディクス、インコーポレイテッド | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 |
| US20040208870A1 (en) | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| AU2004207003A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Llc | Anti-integrin alphanubeta3 antibody formulations and uses thereof |
| WO2005019177A1 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof |
| WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
| US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2006133286A2 (en) | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| PL2034830T3 (pl) * | 2006-05-25 | 2015-04-30 | Biogen Ma Inc | Przeciwciało anty-VLA-1 do leczenia udaru |
| US7626243B2 (en) | 2006-08-04 | 2009-12-01 | Advanced Analogic Technologies, Inc. | ESD protection for bipolar-CMOS-DMOS integrated circuit devices |
| NZ595526A (en) * | 2007-06-14 | 2013-03-28 | Biogen Idec Inc | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant |
| JP4951596B2 (ja) | 2008-07-31 | 2012-06-13 | 株式会社日立製作所 | 冷却システム及び電子装置 |
| EP2331078B1 (en) * | 2008-08-27 | 2012-09-19 | Merck Sharp & Dohme Corp. | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| BR112012013093A2 (pt) * | 2009-12-21 | 2017-12-12 | Genentech Inc | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável |
| NZ602685A (en) * | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
| RU2012153786A (ru) * | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| CN103370081A (zh) | 2011-02-03 | 2013-10-23 | 桑塔鲁斯股份有限公司 | 受试者的选择和治疗 |
| WO2013105161A1 (ja) | 2012-01-11 | 2013-07-18 | パナソニック株式会社 | 圧接型半導体装置及びその製造方法 |
| JP6345123B2 (ja) | 2012-02-16 | 2018-06-20 | サンタラス， インコーポレイテッド | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
-
2013
- 2013-02-14 JP JP2014557754A patent/JP6345123B2/ja not_active Expired - Fee Related
- 2013-02-14 MX MX2014009755A patent/MX370199B/es active IP Right Grant
- 2013-02-14 NZ NZ629204A patent/NZ629204A/en not_active IP Right Cessation
- 2013-02-14 CA CA2864539A patent/CA2864539C/en active Active
- 2013-02-14 US US14/379,095 patent/US10160808B2/en active Active
- 2013-02-14 US US13/766,966 patent/US10316095B2/en active Active
- 2013-02-14 EP EP13711986.3A patent/EP2814468B1/en active Active
- 2013-02-14 WO PCT/US2013/026034 patent/WO2013123114A2/en not_active Ceased
- 2013-02-14 ES ES13711986T patent/ES2732243T3/es active Active
- 2013-02-14 AU AU2013221635A patent/AU2013221635B2/en not_active Ceased
- 2013-02-14 CN CN201380019988.XA patent/CN104271122A/zh active Pending
- 2013-08-30 US US14/015,039 patent/US20140010827A1/en not_active Abandoned
-
2014
- 2014-08-06 IL IL233976A patent/IL233976B/en active IP Right Grant
-
2017
- 2017-11-22 AU AU2017265049A patent/AU2017265049B2/en not_active Ceased
-
2018
- 2018-05-22 JP JP2018097486A patent/JP6759276B2/ja active Active
- 2018-12-20 US US16/227,564 patent/US20190194331A1/en not_active Abandoned
-
2019
- 2019-04-24 US US16/393,171 patent/US20190338036A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508774A5 (https=) | ||
| JP2015519382A5 (https=) | ||
| US11999777B2 (en) | Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies | |
| JP2022532927A5 (https=) | ||
| JP2015157821A5 (https=) | ||
| FI3209681T3 (fi) | Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä | |
| JP2014530226A5 (https=) | ||
| JP2010529026A5 (https=) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| EA201200490A1 (ru) | Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения | |
| JP2019527678A5 (https=) | ||
| JP2014514324A5 (https=) | ||
| NZ755497A (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis | |
| FI3294345T3 (fi) | Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi | |
| JP2018515493A5 (https=) | ||
| JP2018509388A5 (https=) | ||
| JP2019507775A5 (https=) | ||
| JP2015172060A5 (https=) | ||
| JP2017524675A5 (https=) | ||
| KR20240132521A (ko) | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 | |
| Samad et al. | Intracerebral coinfection with Burkholderia pseudomallei and Cryptococcus neoformans in a patient with systemic lupus erythematosus | |
| CN116327925B (zh) | 一种抗狂犬病毒人源抗体的组合制剂及应用 | |
| CN104096229A (zh) | 甘氨酸锌佐剂及含甘氨酸锌佐剂的疫苗 | |
| IL312401A (en) | Methods of treating crohn's disease with anti-il23 specific antibody | |
| CN102085366B (zh) | 一种复合疫苗佐剂 |